AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

benzinga.com/news/health-care/25/11/48761776/astrazenecas-investigational-hypertension-drug-shows-significant-blood-pressure-control-in-pivot

AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.
• AZN is…

This story appeared on benzinga.com, 2025-11-10 18:39:23.
The Entire Business World on a Single Page. Free to Use →